Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Conclusions This study demonstrates that E. multilocularis can induce T‐cell exhaustion
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …

Nonalcoholic fatty liver disease (NAFLD) affects around a quarter of the global population,
paralleling worldwide increases in obesity and metabolic syndrome. NAFLD arises in the …

Based on the assumption that characterizing the history of a disease will help in improving
practice while offering a clue to research, this article aims at reviewing the history of …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, placing an increasing burden on human health. NAFLD is a complex …

The PNPLA3 p. I148M, TM6SF2 p. E167K, and MBOAT7 rs641738 variants represent
genetic risk factors for nonalcoholic fatty liver disease (NAFLD). Here we investigate if these …

There is a high unmet need for developing treatments for nonalcoholic fatty liver disease
(NAFLD), for which there are no approved drugs today. Here, we used a human in vitro …

Objective Homozygous alpha1-antitrypsin (AAT) deficiency increases the risk for developing
cirrhosis, whereas the relevance of heterozygous carriage remains unclear. Hence, we …